Table 2 Clinical characteristics of mast cell sarcoma.
From: Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature
|  | Our study (n = 10) | Literature (n = 24) | Combined (n = 34) |
|---|---|---|---|
Age, Median (years) | 54.5 (1–63) | 39 (4–77), n = 23 | 39 (1–77; n = 33) |
Gender | 5 M, 5 F | 13 M, 11 F | 18 M, 16 F |
Locationsa | |||
  Bone | 9/10 | 12/24 | 21/34 (62%) |
  GI | 0/10 | 7/24 | 7/34 (21%) |
  Soft tissue | 2/10 | 3/24 | 5/34 (15%) |
  Skin | 0/10 | 3/24 | 3/34 (9%) |
  Spleen | 2/10 | 1/24 | 3/34 (9%) |
  Other locations | Brain (1), liver (1), lymph node (1), lung (1) | Peritoneum (3), nasal cavity (2), brain (1), liver (1), lung (1), mid ear (1), subglottis and larynx (1), tonsil (1), uterus/ovaries (1) | Peritoneum (3), brain (2), liver (2), lung (2), nasal cavity (2), lymph node (1), mid ear (1), tonsil (1), uterus/ovaries (1), subglottis and larynx (1) |
 History of SM | 1/9 | 6/21 | 7/30 (23%) |
 B-symptoms | 1/9 | 1/8 | 2/17 (12%) |
 MCAS | 3/9 | 7/13 | 10/22 (45%) |
 Leukemia transformation | 2/9 | 5/21 | 7/30 (23%) |
 BM involvement by MCS | 3/9 | 5/17 | 8/26 (31%) |
 BM involvement by SM | 1/9 | 3/17 | 4/26 (15%) |
 Anemia | 2/7 | 8/12 | 10/19 (53%) |
WBC count | |||
  Normal | 4/6 | 8/12 | 12/18 (67%) |
  Leukocytosis | 2/6 | 2/12 | 4/18 (22%) |
  Leukopenia | 0/6 | 2/12 | 2/18 (11%) |
 Platelet count | |||
  Normal | 5/7 | 7/10 | 12/17 (71%) |
  Thrombocytosis | 0/7 | 3/10 | 3/17 (18%) |
  Thrombocytopenia | 2/7 | 0/10 | 2/17 (12%) |
 Elevated serum tryptase, median and range (ng/ml) | 6/7 132 (34.1–1034) | 11/16 200 (18–400) | 17/23 (74%) 200 (18–1034) |
 Chemotherapy | 7/8 | 16/19 | 23/27 (85%) |
 Radiotherapy | 4/8 | 7/18 | 11/26 (42%) |
Response to therapy | |||
  CR | 0/6 | 3/17 | 3/23 (13) |
  PR | 0/6 | 4/17 | 4/23 (17%) |
  No | 6/6 | 10/17 | 16/23 (70%) |
 Disease progression (yes) | 4/6 | 13/17 | 17/23 (74%) |
 Stem cell transplant | 0/7 | 1/19 | 1/26 (4%) |
 Death | 4/8 | 12/23 | 16/31 (52%) |
 Median follow up (months) | 5 (2–35) | 13 (2–81) | 12 (2–81) |
 Median OS (months) |  |  | 24 |
